Zoloft vs Prozac: How Prescribers Actually Choose

Zoloft and Prozac are both SSRIs, both FDA-approved for depression, and both work by increasing how much serotonin stays active in the brain. If the mechanism is nearly identical, why does one prescriber reach for sertraline and another reach for fluoxetine for two patients with a similar diagnosis?

The answer has almost nothing to do with which drug is “stronger.” It comes down to how each one moves through the body after it’s swallowed: how long it lingers, what it does to the liver enzymes that process other medications, and which specific conditions each one carries FDA approval to treat. Those pharmacokinetic details rarely make it into a patient-facing comparison, but they are exactly what a prescriber is weighing when deciding between the two.

What This Page Covers

• What Zoloft and Prozac Actually Are
• The Half-Life Difference That Changes Everything
• Why Fluoxetine’s Long Half-Life Cuts Both Ways
• Sertraline’s Drug Interaction Profile Is Comparatively Quieter
• Patient-Fit Factors Prescribers Actually Weigh
• About Siggy

What Zoloft and Prozac Actually Are

Zoloft (sertraline) and Prozac (fluoxetine) are both selective serotonin reuptake inhibitors, a class that works by blocking the reabsorption of serotonin in the brain so more of it remains available between neurons. Both are approved for major depressive disorder, but their full FDA-approved indication lists diverge from there.

Sertraline carries a broader label: major depressive disorder, obsessive-compulsive disorder, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric disorder, according to its FDA prescribing information. Fluoxetine’s approved uses are major depressive disorder, obsessive-compulsive disorder, panic disorder, and bulimia nervosa, per its FDA prescribing information, and it is also approved in combination with olanzapine, marketed as Symbyax, for treatment-resistant and bipolar depression. Neither list is a ranking of which drug works better; it reflects which conditions each manufacturer studied and sought approval for.

The Half-Life Difference That Changes Everything

A drug’s half-life is the time it takes for the body to clear half of it from the bloodstream, and this single number explains more about the practical differences between these two medications than almost anything else.

Sertraline has a half-life of about 26 hours, with its active metabolite, desmethylsertraline, lasting 62 to 104 hours, according to the FDA label. Fluoxetine behaves very differently: its own half-life is one to three days after a single dose and stretches to four to six days with regular use, while its active metabolite, norfluoxetine, has a half-life averaging 8.6 to 9.3 days, per the FDA prescribing information.

A brief comparison makes the practical gap clear.

Measure	Sertraline (Zoloft)	Fluoxetine (Prozac)
Parent drug half-life	About 26 hours	1 to 6 days
Active metabolite half-life	62 to 104 hours	8.6 to 9.3 days
Time to steady state	About 1 week	Several weeks
FDA-labeled MAOI washout after stopping	At least 14 days	At least 5 weeks

The FDA label for fluoxetine states plainly that “even when dosing is stopped, active drug substance will persist in the body for weeks,” a warning that does not appear in comparable form on sertraline’s label. Sertraline’s parent drug falls faster, but its longer-lived metabolite is why a one-week shorthand is not an appropriate safety boundary. Medication-specific washout instructions still apply.

Why Fluoxetine’s Long Half-Life Cuts Both Ways

A long half-life is not automatically good or bad. It’s a tradeoff, and it shows up in two very different clinical situations.

On the favorable side, fluoxetine’s slow decline means blood levels fall gradually rather than dropping off sharply, which the FDA label notes “may minimize the risk of discontinuation symptoms” compared with shorter-acting antidepressants. It also makes the occasional missed dose less consequential, since the drug’s built-in buffer keeps levels more stable day to day.

On the other side, that same persistence becomes a liability when a patient needs to start a medication that cannot safely overlap with fluoxetine. The clearest example is switching to a monoamine oxidase inhibitor: because fluoxetine and norfluoxetine can linger for weeks, the FDA label requires a 5-week washout period after stopping fluoxetine before starting an MAOI, longer than the 2-week gap required after stopping sertraline. That timeline is not a formality. It reflects a genuine window where the drug is still active in the body even though the patient has stopped taking it.

Sertraline’s Drug Interaction Profile Is Comparatively Quieter

Beyond half-life, the two drugs differ in how they interact with the liver enzymes that metabolize other medications. Fluoxetine’s FDA label describes it directly as a potent inhibitor of the CYP2D6 enzyme pathway, which is involved in metabolizing a wide range of other drugs. That inhibition can cause normal metabolizers to process certain medications the way a poor metabolizer would, raising blood levels of drugs including some tricyclic antidepressants, antipsychotics, and anticonvulsants. The label documents that this effect can persist for weeks after fluoxetine is discontinued, and it lists thioridazine and pimozide as contraindicated with fluoxetine due to the risk of dangerous heart rhythm changes.

Sertraline’s FDA label also documents CYP interactions, including with CYP2D6 substrates, but its inhibition of that pathway is weaker than fluoxetine’s. This does not mean sertraline is interaction-free. It means the specific pattern of interactions a prescriber needs to screen for looks different depending on which drug is being considered, especially for a patient already taking multiple medications.

Patient-Fit Factors Prescribers Actually Weigh

Beyond half-life and drug interactions, a few other factors commonly tip the decision one way or the other:

• Liver function. Sertraline’s label recommends a lower dose for patients with mild liver impairment and advises against its use in moderate to severe impairment, since it has not been adequately studied in that population.
• Other medications on board. A patient taking a drug that depends on CYP2D6 metabolism, such as certain beta-blockers or antipsychotics, may be steered away from fluoxetine specifically because of its enzyme-inhibiting effect.
• Anxiety-specific approval. A patient with diagnosed PTSD, social anxiety disorder, or panic disorder alongside depression may be a more direct fit for sertraline, since those are FDA-approved indications for the drug specifically, while fluoxetine’s approval for anxiety-adjacent conditions is narrower.
• History with either drug. A patient who previously tolerated one of the two well, or had a difficult experience with one, often has that history weighed heavily in the next prescribing decision.

None of these factors can be sorted out by comparing two drug names online. They depend on a full medication list, lab values, and clinical history that only a prescriber reviewing an individual case can put together.

About Siggy

Sertraline and fluoxetine are both squarely within the SSRI-based depression and anxiety treatment that Siggy is built around. Whichever one a licensed prescriber determines is the better fit, Siggy’s role is to support what happens after that first prescription: tracking side effects, activation symptoms, and mood changes over the first weeks of treatment, and surfacing that information to your prescriber so dose adjustments or a medication change, if needed, happen based on real data rather than a delayed check-in.

If you’re weighing whether your current antidepressant is the right fit, or you’re starting treatment for the first time and want a licensed prescriber involved in that decision, start your anonymous intake with Siggy (https://app.siggymd.ai/start-intake?source=marketing-site).